Trade Names: Zofran Classification: 5-HT3 antagonists Indications: Prevention of nausea and vomiting associated with chemotherapy or radiation

therapy. Actions: Blocks the effects of serotonin at 5-HT3receptor sites (selective antagonist) located in vagal nerve terminals and the chemoreceptor trigger zone in the CNS Therapeutic effects: Decreased incidence and severity of nausea and vomiting following chemotherapy or surgery. Adverse reactions/side effects: CNS: headache, dizziness, drowsiness, fatigue, weakness. GI: constipation, diarrhea, abdominal pain, dry mouth, liver enzymes. Neuro: extrapyramidal reactions. Nursing implications/accountability: Assess patient for nausea, vomiting, abdominal distention, and bowel sounds prior to and following administration. Assess patient for extrapyramidal effects (involuntary movements, facial grimacing, rigidity, shuffling walk, trembling of hands) periodically during therapy. Lab Test Considerations: May cause transient in serum bilirubin, AST, and ALT levels. Patient/family teaching: Instruct patient to take ondansetron as directed. Advise patient to notify health care professional immediately if involuntary movement of eyes, face, or limbs occurs.